

**DESCRIPTION**

**Source** Mouse myeloma cell line, NS0-derived  
 Ser32-Lys314  
 Accession # AAB70793

**N-terminal Sequence Analysis** Ser32, Phe39 (minor) & Asp42 (minor)

**Predicted Molecular Mass** 32.6 kDa

**SPECIFICATIONS**

**SDS-PAGE** 33-40 kDa, reducing conditions

**Activity** Measured by its ability to inhibit proliferation of HeLa human cervical epithelial carcinoma cells. Ko, L. *et al.* (2002) *Exp. Cell Res.* **280**:280. The ED<sub>50</sub> for this effect is typically 0.15-0.75 µg/mL.

**Endotoxin Level** <0.01 EU per 1 µg of the protein by the LAL method.

**Purity** >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

**Formulation** Lyophilized from a 0.2 µm filtered solution in Phosphate and NaCl. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

**Reconstitution** Reconstitute at 250 µg/mL in sterile PBS.

**Shipping** The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage** **Use a manual defrost freezer and avoid repeated freeze-thaw cycles.**

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

**BACKGROUND**

Secreted Frizzled Related Proteins (sFRPs) are a family of secreted, soluble vertebrate glycoproteins which contain homology to the Wnt-binding domain of the Frizzled (Fz) family of transmembrane receptors. sFRPs are approximately 30-35 kDa in size and are comprised of 3 domains: a signal sequence; an N-terminal Fz cysteine-rich domain (CRD) with 10 conserved cysteines; and a C-terminal heparin-binding region with weak homology to Netrin. The Fz CRD mediates Wnt-binding and is present in all Fz and sFRP family members (1).

sFRP-1, also known as secreted apoptosis-related protein 2 (SARP-2), FRP and FrzA, is expressed in the embryonic kidney, eye, brain, teeth, salivary gland and small intestine, most often at sites of epithelial-mesenchyme interaction (5). Expression in the adult animal is strong in the eye, kidney, and heart and also prevalent in the brain and lung (2, 5). sFRP-1 was first characterized as a protein that enhances the sensitivity of cells to apoptotic stimuli (3) and as an antagonist of Wnt signaling in *Xenopus* embryos (4). As such, it is considered to be a potential tumor suppressor in both breast (6) and cervical carcinomas (7). sFRP-1 is also known to be expressed by the majority of malignant gliomas (8) and may contribute to the development of uterine leiomyomas (9). This suggests that the activity of sFRP-1 is context dependent. sFRP-1 has diverse activities, from inducing angiogenesis (10) in a variety of *in vivo* models to helping regulate Wnt-4 signaling (with sFRP-2) in renal organogenesis (11). Mouse and human sFRP-1 proteins share 94% amino acid identity (1).

**References:**

1. Jones, S. *et al.* (2002) *Bioessays* **24**:811.
2. Rattner, A. *et al.* (1997) *Proc. Natl. Acad. Sci. USA* **94**:2859.
3. Melkonyan, H. *et al.* (1997) *Proc. Natl. Acad. Sci. USA* **94**:13636.
4. Finch, P. *et al.* (1997) *Proc. Natl. Acad. Sci. USA* **94**:6770.
5. Leimeister, C. *et al.* (1998) *Mech. Dev.* **75**:29.
6. Ugolini, F. *et al.* (2001) *Oncogene* **20**:5810.
7. Ko, J. *et al.* (2002) *Exp. Cell. Res.* **280**:280.
8. Roth, W. *et al.* (2000) *Oncogene* **19**:4210.
9. Fukuhara, K. *et al.* (2002) *J. Clin. Endocr. Metab.* **87**:1729.
10. Dufourcq, P. *et al.* (2002) *Circulation* **106**: 3097.
11. Yoshino, K. *et al.* (2001) *Mech. Dev.* **102**:45.